Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 14, Issue 5, Pages 569-572Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.2014.896334
Keywords
efficacy; etanercept; side effect; TNF blockers
Ask authors/readers for more resources
TNF blockers have been available to treat various inflammatory disorders since more than a decade. T cells and macrophages mainly express TNF and activate many cells through two types of receptors. Pharmaceutical companies developed two types of TNF blockers: soluble receptors and monoclonal antibodies. Understanding of differences of structure and function can explain divergence of efficacy or side effects. Etanercept has the best retention rate in rheumatic diseases, but is less or not effective in granulomatous diseases, such as inflammatory bowel diseases or uveitis. However, etanercept induces less tuberculosis infections than anti-TNF blocker monoclonal antibodies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available